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and behavioral studies to publish their data sets and com-
mand files is clearly important in context of the prevention
of research waste [1,2]. I fully agree to his proposal, but I
also firmly believe we need to go substantially further.
West focuses on voluntary transparency regarding the data
and the analyses underlying the article at issue. He pro-
vides three reasons why this is important: to protect
against fraud and misrepresentation, to reduce the error
rate, and to facilitate additional analysis. I will argue that
the need for transparency is much broader. Subsequently, I
shall comment on the three reasons given by West. Finally,
I will propose two potentially effective measures to in-
crease transparency.
Science is based on trust. Society must be able to trust
scientists, and scientists should have good reasons to trust
their colleagues [3]. To deserve trust, clinical research
needs to be open, honest, and transparent. The record
should be complete and verifiable. Besides being the basis
for trust, that also will serve as a powerful antidote against
selective reporting. Nonpublication and selective publica-
tion of study outcomes may be the single most important
source of research waste [4e6]. It is also the Achilles heel
of systematic reviews because these rely on the published
reports of research projects. There is evidence that selective
reporting increasingly leads to an overrepresentation of
positive significant findings in the scientific literature
[7,8]. Furthermore, selective reporting is unethical in the
sense that the efforts of patients participating in the study
are wasted. Transparency concerns the whole trajectory:
study protocol, the process of data collection, data sets, data
analysis, report of findings, amendments made underway,
financial and intellectual conflicts of interest, and so forth
[9,10]. The ideal is to make all this information prospec-
tively and publicly available. The proposal by West to pub-
lish the data and the syntax together with the article at issue
offers only limited transparency and will not help a lot in
the prevention of selective reporting. Without a study pro-
tocol that was made publicly available before the start of* Corresponding author.
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0895-4356/ 2016 Elsevier Inc. All rights reserved.the data collection, it is very hard to judge whether all
planned research questions are answered in the published
report. Equally, a data analysis plan that was publicly
deposited before the data were collected is necessary to
judge whether the statistical analysis was not partly data
driven.
I agree that publishing data and syntaxes may serve in
the identification of errors and misrepresentation. However,
it will not do much for the identification of fraud as the data
published may still be fabricated or manipulated. It enables
replication of the data-analyses done by the authors of the
publication at issue and also provides an opportunity to
explore alternative approaches with different cutoff points,
categorizations, or statistical techniques. This certainly is
useful for establishing the robustness of the published find-
ings [11,12]. And if the published data set contains more
than what the authors used for their report, it can also help
in identifying instances of selective publication. Please note
that replication of the data analysis is only one of the forms
replication can take. Other perhaps more important forms
of replication are the collection of new data with the same
study protocol and attempts to answer the same research
questions with another study design and/or in another
setting. Replication by collecting new data is indicated
when the aggregated data from available studies are insuf-
ficient to answer the research question at issue with
adequate validity and precision. If there is already enough
data, the collection of new data is unethical and a waste
of resources.
West makes a distinction between data disclosure and
data sharing. He argues that others have a right to look
for flaws in the data analysis and to publish them when
found. But, he says that the intellectual property rights
should be respected, which means that colleagues will need
permission to use the data to answer other research ques-
tions. I respectfully disagree. I firmly believe that data
collected among volunteering participants of clinical
research belong to the public domain. Of course, some
months of embargo can be reasonable, proper acknowledg-
ments should be made, and maybe the original investigators
should be offered the opportunity to participate in the sec-
ondary analyses. In addition, I agree with West that
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and also that breaches of privacy and misuse of the data
ought to be prevented. And it is obvious that for secondary
analyses, the same rules for transparency apply, starting
with a predefined study protocol. However, all these do
not detract from the principle that data from clinical
research belong in the open domain.
One may wonder how transparency can be promoted
best. Next to good education on responsible conduct of
research on all levels in Academia, there are two ap-
proaches I find promising. First, we should look critically
at the current reward systems and consider alternatives. Sci-
entists gain prestige and get tenure by collecting as much
publications, citations, and grants as possible. Having spec-
tacular and statistically significant results helps them a lot.
Current reward systems do neither focus on replication and
nor on sharing data. In addition, rewards for publishing
study protocols and negative results are nonexistent.
Recently, Ioannidis and Khoury [13] proposed an inter-
esting and more balanced alternative to remedy some of
these perverse incentives.
Second, transparency could be enforced by a
concerted action of granting agencies, institutional re-
view boards, and scientific journals [14]. Demanding a
timely public deposition of study protocol, syntax and
outcome reports as a condition for the last payment, for
permission to perform the study and for accepting the
article for publication, respectively, would obviously be
strong incentives to behave transparent. In the field of
randomized clinical trials, we have seen some progress
in that sense during the last 2 decades. However, there
is still a lot room for improvement, and other types of
studies are lagging behind [15e18]. Especially, the
impact of demands for transparency by funding agencies
may be substantial [19].
We clearly need to collect some more evidence on how
transparency can be realized best. Anddas Robert West
also mentionsdwe need to look into potential drawbacks
and undesired side effects of the interventions proposed.
Including exploring methods to implement transparency
procedures on the Web sites of journals, funding agencies,
or other organizations. Especially, feasible ways of moni-
toring the compliance with the rules for transparency need
to be developed. Consequently, it makes sense to first
experiment on a voluntary basis, with a view to move onto compulsory measures once we understand better how
to nudge and force clinical research in a direction of mini-
mal waste and maximum transparency.
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